What is oligometastatic lung cancer?

Not all metastatic cancer behaves the same way. Some people are diagnosed with oligometastatic non-small cell lung cancer (NSCLC), a specific state of lung cancer where the disease has spread beyond the lung, but only to a limited number of sites in the body.

The term “oligo” itself means “few.” In this context, it refers to cancer that has spread to just a small number of sites. Doctors often use this term when there are only a few metastatic tumors that may be treatable with focused, targeted therapies.

Why this diagnosis can change your treatment plan

In more widespread metastatic lung cancer, treatment usually focuses on systemic therapy, which are medications that travel throughout the body to target cancer cells wherever they may be. With oligometastatic disease, data suggests that a combination approach that incorporates systemic therapy with local ablation may be effective.

Common treatment approaches

Systemic therapy as the primary approach

Most patients with oligometastatic NSCLC receive systemic treatment including:

• Targeted therapy (for cancers with specific genetic mutations)
• Immunotherapy
• Chemotherapy

These options play an essential role in extending the survival of lung cancer patients. Current research is examining how patients with oligometastatic NSCLC can benefit from additional therapies.

Local therapy for metastases

For patients who are responding well to systemic therapy, there’s data that support adding ablative therapies to target specific areas of disease. It’s important to highlight that not everyone is a right fit for the combination approach. Things like performance status, tumor volume, number of metastases, and more should all be considered.

What current research recommends

Currently, there are no standard guidelines for who should receive local therapy in addition to systemic therapy for patients with oligometastatic NSCLC. While data shows ablative therapies benefit survival, ongoing research is actively investigating how to assess who will benefit most from this combination approach. A multidisciplinary approach that takes into account a patient’s overall health, number and location of metastases, tumor biology, response to initial systemic therapy, and personal preferences is essential in guiding treatment decisions and optimizing outcomes.

Questions to ask your doctor

If you’ve been diagnosed with metastatic NSCLC, it may be helpful to ask your care team:

• Do I have oligometastatic disease?
• How many metastatic sites are present?
• Can these tumors be treated with stereotactic body radiation therapy (SBRT), surgery, or another local therapy?
• Are there clinical trials that might be right for me?

These questions can help you better understand your options and feel more confident in your care plan.

Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.